VIVESTO AB (OASMY) 股价，以美元计价

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer. It also provides Doxophos, a patented formulation of cytostatic doxorubicin in combination with XR-17 Doxorubicin for the treatment of various forms of cancers, including blood, skeleton, breast, prostate, and lungs; and KB9520, a substance that is in pre-clinical stage to reduce the side effects of cytostatics treatment. In addition, the company's animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Additionally, its technology platform portfolio comprises XR-19, an internal technology, which is under assessment process for a dual encapsulation technology; and XR-17, a proprietary solubility-enhancing technology platform in oncology and other therapeutic areas. Oasmia Pharmaceutical AB (publ) was founded in 1988 and is headquartered in Uppsala, Sweden.